Back to Search
Start Over
Convalescent plasma anti–SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization
- Source :
- J Clin Invest, bioRxiv, article-version (status) pre, article-version (number) 1
- Publication Year :
- 2020
- Publisher :
- American Society for Clinical Investigation, 2020.
-
Abstract
- Newly emerged pathogens such as SARS-CoV-2 highlight the urgent need for assays that detect levels of neutralizing antibodies that may be protective. We studied the relationship between anti-spike ectodomain (ECD) and anti-receptor binding domain (RBD) IgG titers, and SARS-CoV-2 virus neutralization (VN) titers generated by two different in vitro assays using convalescent plasma samples obtained from 68 COVID-19 patients, including 13 who donated plasma multiple times. Only 23% (16/68) of donors had been hospitalized. We also studied 16 samples from subjects found to have anti-spike protein IgG during surveillance screening of asymptomatic individuals. We report a strong positive correlation between both plasma anti-RBD and anti-ECD IgG titers, and in vitro VN titer. Anti-RBD plasma IgG correlated slightly better than anti-ECD IgG titer with VN titer. The probability of a VN titer ≥160 was 80% or greater with anti-RBD or anti-ECD titers of ≥1:1350. Thirty-seven percent (25/68) of convalescent plasma donors lacked VN titers ≥160, the FDA-recommended level for convalescent plasma used for COVID-19 treatment. Dyspnea, hospitalization, and disease severity were significantly associated with higher VN titer. Frequent donation of convalescent plasma did not significantly decrease either VN or IgG titers. Analysis of 2,814 asymptomatic adults found 27 individuals with anti-RBD or anti-ECD IgG titers of ≥1:1350, and evidence of VN ≥1:160. Taken together, we conclude that anti-RBD or anti-ECD IgG titers can serve as a surrogate for VN titers to identify suitable plasma donors. Plasma anti-RBD or anti-ECD titer of ≥1:1350 may provide critical information about protection against COVID-19 disease.
- Subjects :
- Adult
Male
0301 basic medicine
Adolescent
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Antibodies, Viral
Asymptomatic
Article
Immunoglobulin G
03 medical and health sciences
0302 clinical medicine
medicine
Humans
COVID-19 Serotherapy
Aged
biology
SARS-CoV-2
business.industry
Immunization, Passive
COVID-19
General Medicine
Middle Aged
Acquired immune system
Antibodies, Neutralizing
In vitro
Titer
030104 developmental biology
Ectodomain
030220 oncology & carcinogenesis
Immunology
biology.protein
Female
medicine.symptom
Antibody
business
Research Article
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- J Clin Invest, bioRxiv, article-version (status) pre, article-version (number) 1
- Accession number :
- edsair.doi.dedup.....22021f76c75c2351c162e981d74ff6a8